Trial to Study the Efficacy and Safety of BEJO Red Ginger in COVID-19 Patients With Mild Symptoms

Phase 2

• Conditions: COVID-19
• Interventions: Dietary Supplement: BEJO Red Ginger Extract; Other: Placebo

• Registration Number: NCT05277155
• Lead Sponsor: Research Center for Chemistry, National Research and Innovation Agency of Indonesia

Brief Summary

This study is a randomized, double-blind, placebo-controlled clinical trial to investigate the safety and efficacy of BEJO Red Ginger in hospitalized adult (18 - 50 years old) COVID-19 patients with mild clinical manifestations.

Subjects will be screened during hospitalization. One hundred and sixty-eight patients with confirmed SARS-CoV-2 infection and meeting all criteria, will be recruited to receive either BEJO Red Ginger or placebo in addition to standard of care (SOC) in a 1:1 ratio.

Patients with a diagnosis of COVID-19 and, due to mild symptoms, hospitalized, will be randomized to take a sachet of syrups containing 15 ml of BEJO Red Ginger, 3 times a day: 1 sachet after breakfast, 1 sachet after lunch, and 1 sachet after dinner, as add-on to the SOC, with 2 hours of incubation of SOC. The treatment will last for 14 days or until patients to be declared as cured. The treated patients will be compared with an equal group treated with placebo and SOC. Recovery time, symptoms, and objective (inflammatory) parameters (see detailed description) will be analyzed as outcomes. The goal of this study is to evaluate the role of BEJO Red Ginger in preventing progression of COVID-19 and accelerating healing process in patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-22
• Status Verified: 2022-03
• Study First Submitted: 2022-03-04
• Study First Submitted QC: 2022-03-11
• Last Update Submitted: 2022-03-11
• Study First Posted: 2022-03-14
• Last Update Posted: 2022-03-14
• Primary Completion: 2022-07-22
• Study Completion: 2022-08-22

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 168

Inclusion Criteria

• Age 18 to 50 years, both sexes.
• Newly diagnosed adult patients with positive SARS-COV-2 by Real Time-PCR, using an appropriate sample such as nasopharyngeal, oropharyngeal, or nasal swab (within 3 days prior to study enrolment).
• Patients diagnosed with mild clinical manifestations, according to the Management of COVID-19 patients issued by The Indonesian Society of Respirology (Kepmenkes HK.0107/MENKES/5671/2021). Mild symptoms including fever, cough, shortness of breath, myalgia, sore throat, anosmia, diarrhea, nauseous and other symptoms.
• Hospitalized patients.
• Subject must have provided written informed consent which includes signing the institutional review board approved consent form prior to participating.

Exclusion Criteria

• Asymptomatic COVID-19 patients

• Presence of any of the following abnormal laboratory values:

  • Elevation in serum glutamic oxaloacetic transaminase (SGOT) and/ or serum glutamic pyruvic transaminase (SGPT) of greater than 5 times the upper limit of normal (SGOT normal value 34 - 45 UI; SGPT normal value 31 - 35 UI)
  • Elevation in urea and creatinine blood levels of greater than the upper limit of normal (Urea normal value 10 - 44 mg/dL; creatinine normal value 0.4 - 1.4 mg/dL)

• Patients with severe pneumonia.

• Patients with serious co-morbidity, including: coronary heart diseases, congestive heart failure, arrhythmia, liver diseases, hypertension, diabetes mellitus (DM) type 1 and 2, glucocorticoid-induced DM, geriatric syndromes, autoimmune diseases, severe renal impairment, myocardial infarction, chronic obstructive pulmonary diseases (including asthma, tuberculosis) , and malignancies. The medical history was determined by from the statement of prospective subjects.

• Patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), proved by an electrocardiogram (ECG) result.

• Be pregnant, confirmed with a negative pregnancy test.

• Lactating and breast feeding.

• Has consumed, or consuming herbal medicines or supplements other than SOC for COVID-10 in RSDC Wisma Atlet.

• Patient who has allergies to the test product.

• Active participation in other drug clinical trials.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention Group (BEJO Red Ginger Extract)	BEJO Red Ginger Extract	84 patients, dosage: BEJO Red Ginger Extract orally administrated 3 times a day each 15 mL plus the standard COVID-19 treatment as per hospital guideline with 2 hours interval time. (Time frame: from randomization to day 14 or until hospital discharge)
Control Group (Placebo)	Placebo	84 patients, dosage: Placebo orally administrated 3 times a day each 15 mL plus the standard COVID-19 treatment as per hospital guideline with 2 hours interval time. (Time frame: from randomization to day 14 or until hospital discharge)

Primary Outcome Measures

Name	Time	Method
Nucleic acid conversion time from randomization to the date of negative RT-PCR test result on the determined examinations.	from randomization to day 14 or until hospital discharge

Secondary Outcome Measures

Name	Time	Method
Assessment of TNF-alfa level	from randomization to day 14 or until hospital discharge	Changes from baseline in TNF-alfa
Clinical improvement; from initiation of study treatment (active or placebo) and daily anamnesis.	from randomization to day 14 or until hospital discharge	Time to clinical improvement, defined as the time from randomization to improvement of subjects' clinical status.
Assessment of IL-6 level	from randomization to day 14 or until hospital discharge	Changes from baseline in IL-6

Trial Locations

Locations (1)

RSDC Wisma Atlet Kemayoran; 🇮🇩 Jakarta, Indonesia